The timing, perhaps, is everything. Just as Europe's hospitals struggle to plug persistent gaps in their nursing rosters—a hangover from pandemic-era burnout that shows few signs of abating—Paris-based Hublo has closed a €20 million Series B round from Bpifrance Equity MidCap.
The October 2025 investment lands barely three months after Five Arrows, Rothschild & Co's private equity arm, took a majority stake in the healthcare workforce management platform. For a company serving more than 5,000 facilities and one million healthcare professionals across Europe, the rapid-fire dealmaking suggests momentum. Or at least the appearance of it.
Hublo's pitch is straightforward, if not exactly novel: software to ease the daily chaos of shift scheduling, recruitment, and internal staff redeployment—tasks that consume hours of administrator time and leave hospital managers perpetually juggling phones and spreadsheets. The platform bundles ad-hoc and recurring staffing needs, recruitment tools under its Mstaff brand, communications, and crisis features like mass recall capabilities when emergencies strike.
The company claims users save roughly 2.5 hours daily. More than 22,000 managers now rely on the system, according to Hublo. Revenue hit €22 million in 2024, with the firm eyeing north of €30 million in annual recurring revenue this year.
A Merger-Driven Expansion Play
Hublo itself emerged from a 2021 union of two regional players: Whoog, based in Sophia Antipolis, and medGo out of Paris. Since then, it's been stitching together competitors with notable urgency. This past April, the company snapped up both Permuteo and Staffea, integrating their features into its expanding platform.
Co-CEOs Antoine Loron and Adrien Beata, both medGo co-founders, have steered the consolidation strategy. The company employs between 180 and 200 people spread across six countries, including offices in Paris, Cologne, and Barcelona. It earned B Corporation certification in September 2023 and bills itself as an "entreprise à mission"—France's corporate designation for businesses with a social purpose baked into their bylaws.
All of which positions Hublo for the kind of pan-European expansion that requires capital. Lots of it.
Investor Musical Chairs
The funding history gets a bit tangled. Hublo raised a €22 million Series A in 2021 from Revaia (then known as Gaia Capital Partners) and Munich's Acton Capital. When Five Arrows bought its majority stake mid-2025, Acton exited. Revaia, however, doubled down—closing a €40 million reinvestment vehicle in February 2026 to back Hublo's next phase under new ownership.
The Bpifrance check represents fresh outside validation, though growth equity investors rarely need much convincing these days when it comes to healthcare infrastructure software. The market for workforce management tools in the sector is projected to balloon from roughly $2.5 billion in 2025 to around $5.2 billion by 2034, per Precedence Research estimates.
A Market Shaped by Scarcity
The opportunity is, in a word, structural. Europe's healthcare systems have been hemorrhaging staff—nurses especially—since COVID-19 upended working conditions and accelerated retirements. What began as a temporary crisis has hardened into a chronic shortage, forcing hospitals to lean harder on temp agencies, overtime shifts, and increasingly, software to optimize who's working when.
Across the Atlantic, the stakes—and valuations—have grown eye-popping. Last August, Hearst acquired U.S.-based QGenda, a scheduling and credentialing platform, for somewhere between $2 billion and $3 billion. In Europe, Berlin's Medwing, a recruitment marketplace, raised a $47 million Series C back in 2022, signaling sustained investor appetite well before Hublo's recent flurry of activity.
Still, Hublo faces entrenched hospital management systems and the inertia that comes with them. The next test will be whether its product can do more than just schedule shifts—whether it can, as the company hopes, become indispensable infrastructure across European healthcare. That's the bet Bpifrance and Five Arrows are making, anyway.
For now, Hublo has capital to deepen its presence and add functionality. Whether that translates to the kind of market dominance that justifies all the M&A and fundraising remains an open question. One thing's certain, though: Europe's hospitals aren't solving their staffing problems on their own anytime soon.
